We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Brand manufacturer Acorda is fending off at least six different generic challenges filed in the last few weeks to its multiple sclerosis drug Ampyra. Read More
AbbVie’s persistent courtship of Irish drugmaker Shire paid off with a roughly $54 billion merger that gives the U.S. company access to a promising rare disease drug pipeline and a more tax-friendly climate. Read More
The price of Gilead’s hepatitis C drug Sovaldi once again is drawing bipartisan fire from Capitol Hill, this time from two senators who are demanding answers as to how the company arrived at the product’s $1,000-a-pill price tag. Read More
Abbott Laboratories is sharpening its focus on devices and diagnostics, selling its developed markets generic drug business to Mylan for $5.3 billion in stock. Read More
Pfizer is facing at least three class action lawsuits alleging that the company went to extraordinary, fraudulent lengths to maintain exclusivity over its multibillion dollar arthritis pain drug Celebrex and keep generic competitors off the market. Read More
A group of third-party pharmaceutical payers is moving to settle part of a class action lawsuit against Pfizer-subsidiary King Pharmaceuticals and generics maker Mutual Pharmaceutical over their alleged collusion to delay a generic of the muscle relaxant Skelaxin. Read More